Oncotype DX Testing Lets Some Breast Ca Patients Skip Chemo

cp418

http://www.medpagetoday.com/HematologyOncology/Bre...

Oncotype DX Testing Lets Some Breast Ca Patients Skip Chemo

Low 21-gene score meant 98% disease-free survival with endocrine therapy alone

wallycat

So same information. I thought (perhaps mistakenly) that the point of the TailorX study was to see if intermediates benefited from chemo or where the "cut off" line should be for "no chemo."

We already KNEW low score gals would do well without chemo. I sure wish they would focus on the task at hand. SOrry for venting.

Fallleaves

Well, that's good that low-score people with even node-positive and high grade cancer can avoid chemo. But why don't they give specific numbers for the sub-groups? And like Wallycat, I wish they'd look at mid and high- score people, too.

farmerlucy

"This research was financially supported by Genomic Health, makers of the Oncotype Dx assay."

Also a three year disease-free survival does not sound that long, especially considering the growth rate of tumors with low RS.

Interesting article, especially the way they discount "grade" and Ki-67 - but you would expect that from Genomic Health. Hmmm.